<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70608">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02052141</url>
  </required_header>
  <id_info>
    <org_study_id>0624-301</org_study_id>
    <nct_id>NCT02052141</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema</brief_title>
  <official_title>A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Romania: National Agency for Medicines and Medical Devices</authority>
    <authority>Mexico: Federal Commission for Protection Against Health Risks</authority>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective - To assess the relative efficacy of two dose levels of CINRYZE (500 Units
      and 1000 Units) administered by intravenous (IV) injection every 3 or 4 days to prevent
      angioedema attacks in children 6 to 11 years of age with hereditary angioedema (HAE).

      Secondary Objectives - To assess the safety and tolerability, characterize the
      pharmacokinetics (PK) and pharmacodynamics (PD), and assess the immunogenicity of two dose
      levels of CINRYZE administered by IV injection in children 6 to 11 years of age with HAE.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of angioedema attacks in each treatment period</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events by dose group</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in C1 inhibitor (C1 INH) and C4 concentrations during each treatment period</measure>
    <time_frame>Pre-dose to 1 hour post-dose at Visit 1, Week 6, and Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with C1 INH antibodies</measure>
    <time_frame>28 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>500 Units First, Then 1000 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1000 Units First, Then 500 Units</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 Units of CINRYZE administered by IV injection twice per week for 12 weeks followed by 500 Units of CINRYZE administered by IV injection twice per week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CINRYZE</intervention_name>
    <arm_group_label>500 Units First, Then 1000 Units</arm_group_label>
    <arm_group_label>1000 Units First, Then 500 Units</arm_group_label>
    <other_name>C1 esterase inhibitor (human)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type I or Type II HAE.

          -  History of angioedema attacks.

        Exclusion Criteria:

          -  History of bleeding or clotting abnormality.

          -  Diagnosis of acquired angioedema or known to have C1 INH antibodies.

          -  History of allergic reaction to C1 esterase inhibitor or other blood products.

          -  Receipt of any experimental agents other than those required for prevention or
             treatment of angioedema attacks within 30 days prior to screening.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martino Laurenzi, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>ViroPharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>866-331-5637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>866-331-5637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>866-331-5637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>866-331-5637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>866-331-5637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>866-331-5637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1431FWN</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>+1 866-331-5637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>+32 2 747 09 71</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>+32 2 747 09 71</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Mörfelden-Walldorf</city>
        <zip>64546</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>+32 2 747 09 71</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Salerno</city>
        <zip>84131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>+32 2 747 09 71</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Mexico City</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>+1 866-331-5637</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Targu-Mures</city>
        <zip>540072</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>+32 2 747 09 71</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ViroPharma Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ViroPharma Clinical Operations</last_name>
      <phone>+32 2 747 09 71</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Argentina</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>HAE</keyword>
  <keyword>Cinryze</keyword>
  <keyword>C1 inhibitor</keyword>
  <keyword>C1 INH</keyword>
  <keyword>Prevention</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Complement C1 Inactivator Proteins</mesh_term>
    <mesh_term>Complement C1 Inhibitor Protein</mesh_term>
    <mesh_term>Complement C1</mesh_term>
    <mesh_term>Complement C1s</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
